Cover Image
市場調查報告書

單株抗體相關的各種合作契約:契約條件·協定內容

Global Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 256416
出版日期 內容資訊 英文 510 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
單株抗體相關的各種合作契約:契約條件·協定內容 Global Monoclonal Antibody Partnering Terms and Agreements 2010-2016: Deal trends, players and financials
出版日期: 2016年09月01日 內容資訊: 英文 510 Pages
簡介

本報告提供單株抗體相關各種合作契約調查分析,提供近幾年的各種契約趨勢,大規模契約及大醫藥品經營者的契約概要,契約區分·開發現階段·治療領域·各技術類型的名錄等彙整資料,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 單株抗體相關各種契約動向

  • 簡介
  • 過去數年的單株抗體相關合作
  • 大製藥公司的契約活動
  • 對單株抗體不積極的大型製藥公司
  • 單株抗體相關合作:各類型契約
  • 單株抗體相關合作:各適應症
  • 單株抗體的平均契約條件

第3章 主要契約

  • 簡介
  • 主要契約:各交易金額

第4章 大型製藥公司的單株抗體契約

  • 簡介
  • 大型製藥公司的單株抗體合作契約的利用法
  • 大型製藥公司的單株抗體合作企業簡介

第5章 大生物工學的單株抗體契約

第6章 單株抗體合作契約名錄

  • 簡介
  • 企業A-Z
  • 各類型契約
  • 各開發階段
  • 各治療領域

第7章 單株抗體契約:各技術類型

第8章 單株抗體的合作機會

  • 網路夥伴合作
  • 合作夥伴活動
  • 相關資料

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP21131

The ‘Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the monoclonal antibodies partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016: Deal trends, players, financials and forecasts’ report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest monoclonal antibody agreements announced in the healthcare sectors, covering:

  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all monoclonal antibody partnering deals announced since Jan 2010, including financial terms where available, including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of monoclonal antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in monoclonal antibody dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading monoclonal antibody deals since 2010. Deals are listed by headline value, signed by big pharma, most active monoclonal antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in monoclonal antibody dealmaking with a brief summary followed by a comprehensive listing of monoclonal antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of monoclonal antibody partnering deals signed and announced since Jan 2010. The chapter is organized by specific monoclonal antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by monoclonal antibody partnering company A-Z, deal type definitions and monoclonal antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of monoclonal antibody technologies and products.

Key benefits

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Access to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world's biopharma companies
  • Identify the leading monoclonal antibody partnering companies
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
<

>Report scope>

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ is intended to provide the reader with an in- depth understanding and access to monoclonal antibodies trends and structure of deals entered into by leading companies worldwide.

‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’ includes:

  • Trends in monoclonal antibodies dealmaking in the biopharma industry since 2010
  • Analysis of monoclonal antibodies deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 700 monoclonal antibodies deal records
  • The leading monoclonal antibodies deals by value since 2010
  • Includes chimeric mAb, humanized mAb, human mAb and murine mAb deals and alliances since 2010

In ‘Global Monoclonal antibody Partnering Terms and Agreements 2010 to 2016’, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Monoclonal antibodies type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 700 monoclonal antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise monoclonal antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Monoclonal Antibody Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of monoclonal antibodies deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Acces to the structure of monoclonal antibodies agreements with numerous real life case studies
  • Comprehensive access to over 700 actual monoclonal antibodies deals entered into by the world's biopharma companies, together with real world clause examples
  • Full listing of monoclonal antibodies deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading monoclonal antibodies deals by value since 2010
  • Identify the most active monoclonal antibodies dealmakers since 2010
  • Insight into the terms included in a monoclonal antibodies agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in monoclonal antibody dealmaking

  • 2.1. Introduction
  • 2.2. Monoclonal antibody partnering over the years
  • 2.3. Most active monoclonal antibody dealmakers
  • 2.4. Monoclonal antibody partnering by deal type
  • 2.5. Monoclonal antibody partnering by therapy area
  • 2.6. Deal terms for monoclonal antibody partnering
    • 2.6.1 Monoclonal antibody partnering headline values
    • 2.6.2 Monoclonal antibody deal upfront payments
    • 2.6.3 Monoclonal antibody deal milestone payments
    • 2.6.4 Monoclonal antibody royalty rates

Chapter 3 - Leading monoclonal antibody deals

  • 3.1. Introduction
  • 3.2. Top monoclonal antibody deals by value

Chapter 4 - Most active monoclonal antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active monoclonal antibody dealmakers
  • 4.3. Most active monoclonal antibody partnering company profiles

Chapter 5 - Monoclonal antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Monoclonal antibody contracts dealmaking directory

Chapter 6 - Monoclonal antibody dealmaking by technology type

  • Monoclonal antibodies
  • Chimeric mAb
  • Humanized mAb
  • Human mAb
  • Murine mAb

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Monoclonal antibody deals by company A-Z
  • Appendix 2 - Monoclonal antibody deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Monoclonal antibody deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Loan
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Appendix 4 - Monoclonal antibody deals by therapy area
  • Cardiovascular
  • Central Nervous System
  • Dental
  • Dermatology
  • Gastrointestinal
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Metabolic
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Respiratory
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Monoclonal antibody partnering since 2010
  • Figure 3: Active monoclonal antibody dealmaking activity- 2010 to 2016
  • Figure 4: Monoclonal antibody partnering by deal type since 2010
  • Figure 5: Monoclonal antibody partnering by disease type since 2010
  • Figure 6: Monoclonal antibody deals with a headline value
  • Figure 7: Monoclonal antibody deals with an upfront value
  • Figure 8: Monoclonal antibody deals with a milestone value
  • Figure 9: Monoclonal antibody deals with a royalty rate value
  • Figure 10: Top monoclonal antibody deals by value since 2010
  • Figure 11: Most active monoclonal antibody dealmakers 2010 to 2016
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top